Features

Features

Debates, in-depth articles, and surprising profiles from ASH Clinical News

High Hopes

Hematology patients are turning to cannabis for symptom relief, but should they? As of October 2017, 28 states and the District of Columbia had...

A Behind-the-Scenes Look at the ASH Annual Meeting

Every December, tens of thousands of researchers, clinicians, and health-care stakeholders gather for the American Society of Hematology’s (ASH) annual meeting. More than a...

When Life Gives You Venoms… : Mrinal Patnaik, MBBS

In this edition, Mrinal Patnaik, MBBS, explains his fascination with snakes and how venomous reptiles have contributed to hematology. Dr. Patnaik is associate professor...

Fighting for Hematology: ASH Bridge Grants and Grassroots Advocacy

After years of across-the-board funding cuts and steady budget declines, the National Institutes of Health (NIH) received a $2 billion increase in funding with...

Off to the CAR T Races: Bringing CAR T-Cell Therapies to Cancer Patients

August 30, 2017, marked a milestone for medicine: The cell-based gene therapy tisagenlecleucel became the first U.S. Food and Drug Administration (FDA)–approved treatment that...

Pulling Back the Curtain: Donna DiMichele, MD

In this edition, Donna DiMichele, MD, reveals the careers she imagined herself in had she not pursued medicine, and how her first summer jobs...

The Pains of Opioid Prescribing

The United States is in a state of emergency: The Centers for Disease Control and Prevention (CDC) estimates that 91 Americans die each day...

The Rank Tank

Are public health-care ratings an indicator of quality or of popularity? Each summer, U.S. News & World Report releases its list of the best hospitals...

Mining the “Gold Rush” of Immunotherapy Clinical Trials

Immunotherapy has the potential to revolutionize cancer treatment, but as the number of immunotherapy clinical trials continues to grow, so do the challenges and...

Entering A New Era of Immunotherapy

On August 30, 2017, the FDA approved the first gene therapy in the United States: Tisagenlecleucel (Kymriah, Novartis) is a CD19-directed CAR T-cell therapy...
Advertisement

Current Issue

November 2017, Volume 3, Issue 13

This issue features a behind-the-scenes look at the ASH annual meeting, bringing newly approved gene therapies to patients, and more.